Sysmex Inostics has launched its SafeSeq Breast Cancer and Head and Neck Cancer Panels, which both run on the firm's next-generation sequencing SafeSeq platform. The SafeSeq Breast Cancer Panel tests for mutations affecting the PIK3CA, ESR1, TP53, ERBB2, AKT1, and KRAS genes in ER-positive HER2-negative breast cancer samples, the firm noted. The SafeSEQ Breast cancer panel offers sensitive detection of mutant ctDNA, which Sysmex believes is well suited for disease monitoring to assess treatment response, minimal residual disease, and molecular relapse. Sysmex's SafeSeq Head and Neck Cancer panel tests for mutations in the genes PIK3CA, CDKN2A, HRAS, and TP53.
In addition to the cancer panels, Sysmex now offers its SafeSeq Rapid Custom Development program for circulating tumor DNA (ctDNA) analysis. The firm said that users can assemble targeted genes and mutations into highly sensitive fit-for-purpose assays with customer-selected levels of analytical and clinical validation.